Study Title

A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

Study Number

GI011

Enrollment status

Coming Soon

Categories

Metastatic Disease, Pancreatic

Study Summary

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care options include additional chemotherapy, observation, or standard lower-dose radiation therapy. These treatments may delay tumor growth but have not been shown to improve survival. Radiation therapy uses high energy X-rays to kill cancer cells and shrink tumors. Dose-escalated radiation therapy involves the precise delivery of higher doses to the tumor, often over a shorter period of time. This trial assesses whether using dose-escalated radiation therapy can prolong survival.

Study Coordinator(s)

  • Navigator Carrie, 309-243-3621 cgeoffroy@illinoiscancercare.com
  • Jessica, 309-243-3615, jjones@illinoiscancercare.com

Study Link

View Study Details

Additional Information

RT Credentialed at OSF (Glen Oak and Route 91)